Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
13 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Changes in Registrant's Certifying Accountant
10 Apr 24
8-K
Other Events
29 Mar 24
424B5
Prospectus supplement for primary offering
29 Mar 24
S-8
Registration of securities for employees
28 Mar 24
8-K
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
28 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
EFFECT
Notice of effectiveness
12 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
S-3
Shelf registration
31 Jan 24
8-K/A
CalciMedica Announces Private Placement of up to Approximately $55 Million
24 Jan 24
8-K
CalciMedica Announces Private Placement of up to Approximately $55 Million
22 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
9 Nov 23
8-K
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
2 Nov 23
EFFECT
Notice of effectiveness
21 Aug 23
CORRESP
Correspondence with SEC
16 Aug 23
UPLOAD
Letter from SEC
15 Aug 23
S-3
Shelf registration
11 Aug 23
8-K
Other Events
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
10 Aug 23
ARS
2022 FY
Annual report to shareholders
28 Jun 23
DEFA14A
Additional proxy soliciting materials
28 Jun 23
DEF 14A
Definitive proxy
28 Jun 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
27 Jun 23
8-K
Regulation FD Disclosure
15 Jun 23
CERT
Certification of approval for exchange listing
13 Jun 23
8-A12B
Registration of securities on exchange
13 Jun 23
8-K
CalciMedica Announces Relisting on Nasdaq
12 Jun 23
8-K
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
15 May 23
S-8
Registration of securities for employees
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K/A
Report of Independent Registered Public Accounting Firm
12 May 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
12 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 May 23
EFFECT
Notice of effectiveness
17 Apr 23
Latest ownership filings
4
Daniel E. Geffken
20 May 24
4
Frederic Guerard
22 Apr 24
4
ERIC BJERKHOLT
22 Apr 24
4
Allan Shaw
22 Apr 24
4
FRED A MIDDLETON
22 Apr 24
4
ROBERT N WILSON
22 Apr 24
4
Michael J. Dunn
22 Apr 24
4
Kenneth A. Stauderman
22 Apr 24
4
Eric W Roberts
22 Apr 24
4
Sudarshan Hebbar
22 Apr 24
4
A. Rachel Leheny
22 Apr 24
4
Eric W Roberts
2 Apr 24
SC 13D/A
Valence Investments SPV VI, LLC
8 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
8 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Eric W Roberts
6 Feb 24
SC 13D/A
ORBIMED ADVISORS LLC
5 Feb 24
SC 13G
Flynn James E
1 Feb 24
SC 13G
Aisling Capital V, LP
1 Feb 24
SC 13G
Stonepine Capital Management, LLC
31 Jan 24
SC 13G
Soleus Capital Master Fund, L.P.
26 Jan 24
4
FRED A MIDDLETON
25 Jan 24
4
Ventures Management VI Sanderling
25 Jan 24
4
A. Rachel Leheny
25 Jan 24
4
ROBERT N WILSON
25 Jan 24
4
ROBERT N WILSON
13 Dec 23
SC 13D/A
Valence Investments SPV VI, LLC
22 Nov 23
4
A. Rachel Leheny
8 Nov 23
4
Eric W Roberts
8 Nov 23
4
Eric W Roberts
7 Nov 23
4
A. Rachel Leheny
7 Nov 23
4
Sudarshan Hebbar
7 Nov 23
4
Eric W Roberts
6 Nov 23
4
A. Rachel Leheny
6 Nov 23
4
Ventures Management VI Sanderling
10 Oct 23
3
Ventures Management VI Sanderling
10 Oct 23
4/A
Eric W Roberts
5 Sep 23
4
Eric W Roberts
29 Aug 23
4
Eric W Roberts
23 Aug 23
4
ROBERT N WILSON
28 Jun 23